IMMUNOTHERAPY OF LUNG CANCER: ALONE OR IN COMBINATION?

ROOM 311
SUNTEC, SINGAPORE

Chairs:
Tetsuya Mitsudomi, Japan
David Planchard, France

FRIDAY, 23 NOVEMBER 2018
12:45 - 14:15

12:45 Introduction
Tetsuya Mitsudomi, Osaka, Japan

12:50 1st line immunotherapy options for patients without an oncogene driver
Ross Soo, Singapore

13:10 What is the biological rationale for combining chemotherapy with immune checkpoints (ICPs) inhibitors?
Marina Garassino, Milan, Italy

13:30 Are ICPs better as single agent, doublet ICPs or combined with chemo +/- anti-angiogenics?
Solange Peters, Lausanne, Switzerland

13:50 What’s new in the guidelines for immune therapy of metastatic NSCLC?
David Planchard, Villejuif, France

14:10 Conclusions
Tetsuya Mitsudomi, Osaka, Japan